2.44
+0.03(+1.24%)
Currency In USD
| Previous Close | 2.41 |
| Open | 2.42 |
| Day High | 2.52 |
| Day Low | 2.4 |
| 52-Week High | 6.01 |
| 52-Week Low | 1.15 |
| Volume | 354,542 |
| Average Volume | 464,912 |
| Market Cap | 42.18M |
| PE | -1.06 |
| EPS | -2.31 |
| Moving Average 50 Days | 2.85 |
| Moving Average 200 Days | 2.65 |
| Change | 0.03 |
If you invested $1000 in NRx Pharmaceuticals, Inc. (NRXP) since IPO date, it would be worth $25.42 as of December 05, 2025 at a share price of $2.44. Whereas If you bought $1000 worth of NRx Pharmaceuticals, Inc. (NRXP) shares 5 years ago, it would be worth $22.5 as of December 05, 2025 at a share price of $2.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
GlobeNewswire Inc.
Dec 03, 2025 12:00 PM GMT
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS).NRx has amended its Investigational New Drug filing for NRX-101
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
GlobeNewswire Inc.
Dec 02, 2025 1:30 PM GMT
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use of KETAFREE™ as a proprietary product name, which is s
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
GlobeNewswire Inc.
Dec 02, 2025 12:30 PM GMT
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on